Abstract
Clinical data from 14 randomized double-blind studies were reviewed to compare the renatl tolerance of non-ionic monomeric contrast agents (iopamidol 300, iopromide 300, iohexol 300) with the non-ionic dimer iotrolan 280. A prospective study of iotrolan 280 versus iohexol 300 in renally impaired patients was also evaluated. Differences between the contrast agents were investigated using sub-group analysis of patients with an increased risk of contrast-induced nephropathy. Both the prospective study and meta-analysis of previous studies indicate that iotrolan 280 has less influence on renal function than the non-ionic monomeric comparator agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
